CN108477611A - 一种用于治疗、预防和/或修复癌症的复方小球藻组合物 - Google Patents
一种用于治疗、预防和/或修复癌症的复方小球藻组合物 Download PDFInfo
- Publication number
- CN108477611A CN108477611A CN201810205334.0A CN201810205334A CN108477611A CN 108477611 A CN108477611 A CN 108477611A CN 201810205334 A CN201810205334 A CN 201810205334A CN 108477611 A CN108477611 A CN 108477611A
- Authority
- CN
- China
- Prior art keywords
- chlorella
- cancer
- selenium
- compound
- repairing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 43
- 201000011510 cancer Diseases 0.000 title claims abstract description 38
- 241000195649 Chlorella <Chlorellales> Species 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 241001145025 Saussurea involucrata Species 0.000 claims abstract description 60
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 55
- 239000011669 selenium Substances 0.000 claims abstract description 55
- 150000004676 glycans Chemical class 0.000 claims abstract description 38
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 38
- 239000005017 polysaccharide Substances 0.000 claims abstract description 38
- 239000000843 powder Substances 0.000 claims abstract description 38
- 241000222684 Grifola Species 0.000 claims abstract description 37
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 33
- 241000233866 Fungi Species 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 244000249214 Chlorella pyrenoidosa Species 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 25
- 235000019441 ethanol Nutrition 0.000 claims description 21
- 230000008676 import Effects 0.000 claims description 21
- 238000011534 incubation Methods 0.000 claims description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 240000001080 Grifola frondosa Species 0.000 claims description 19
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 19
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 14
- 239000001569 carbon dioxide Substances 0.000 claims description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 238000001694 spray drying Methods 0.000 claims description 12
- 241000195493 Cryptophyta Species 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 229930003944 flavone Natural products 0.000 claims description 8
- 235000011949 flavones Nutrition 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 7
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 7
- 239000001354 calcium citrate Substances 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- 235000013877 carbamide Nutrition 0.000 claims description 7
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 7
- 239000011790 ferrous sulphate Substances 0.000 claims description 7
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 150000002212 flavone derivatives Chemical class 0.000 claims description 7
- 235000001727 glucose Nutrition 0.000 claims description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 7
- 230000002045 lasting effect Effects 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 7
- 206010013786 Dry skin Diseases 0.000 claims description 6
- 238000009360 aquaculture Methods 0.000 claims description 6
- 244000144974 aquaculture Species 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- 235000011008 sodium phosphates Nutrition 0.000 claims description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 6
- 230000008439 repair process Effects 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 4
- 239000008399 tap water Substances 0.000 claims description 4
- 235000020679 tap water Nutrition 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract description 5
- 230000001093 anti-cancer Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 239000011573 trace mineral Substances 0.000 abstract description 4
- 235000013619 trace mineral Nutrition 0.000 abstract description 4
- 230000000295 complement effect Effects 0.000 abstract description 3
- 210000000987 immune system Anatomy 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 150000003254 radicals Chemical class 0.000 abstract description 2
- 230000002829 reductive effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 241000195652 Auxenochlorella pyrenoidosa Species 0.000 abstract 2
- 230000008961 swelling Effects 0.000 abstract 1
- 229960004424 carbon dioxide Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 229920001503 Glucan Polymers 0.000 description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- -1 lignanoid Chemical class 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920000018 Callose Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗、预防和/或修复癌症的复方小球藻组合物。所述用于治疗、预防和/或修复癌症的复方小球藻组合物按照质量份数包括：蛋白核小球藻粉30～70份、雪莲培养物10～30份和富硒灰树花真菌多糖提取物15～45份。本发明以蛋白核小球藻纯粉为主，天山雪莲为辅，配合治疗兼证，灰树花协同真菌多糖活化免疫系统，配合抑制病毒在体内复制，中和或转化自由基的物质的微量元素硒，各生物营养有效成分优势互补，该组合物成本低，效果好，无副作用，能够增强人体免疫力，逐渐缩小癌肿肿块，减少病人痛苦，有助于治疗、预防癌症及修复癌症对人体造成的损伤。
Description
技术领域
本发明涉及中药食品技术领域，具体涉及一种用于治疗、预防和/或修复癌症的复方小球藻组合物。
背景技术
据国际抗癌联盟公布数据显示，目前全球癌症死亡人数占总死亡人数的近六分之一，每年有1400多万新发癌症病例，预计到2030年这一数字将增加到2100多万。中国癌症中心将来源于72个地区的以人口为基础的癌症注册数据，来估算新发肿瘤病例和死亡病例显示，仅在2015年，我国共有429.2万新发肿瘤病例和281.4万癌症死亡病例，以肺癌为发病率最高，并且肺癌的死亡率也排在各种不同肿瘤类型之首。
目前治疗癌症的主要手段是手术、化疗、放疗及其他综合治疗方法。其他综合治疗方法包括内分泌治疗、免疫治疗、生物治疗、中西医结合治疗等方法。在这些方法中，西医治疗的优势在于见效快，但常因西药治疗导致事与愿违的不良后果，并且副作用严重者可引起单系统或多系统功能衰竭。中医优势在于缓解症状的效果平稳，对癌症放化疗当中的继发医源性损害有良好的辅助治疗作用，此外，来源于阳光、空气、水、自然界的有机和无机物质资源是维持人类的健康物质基础，只有正确的运用和摄入，才能构建好的身体状态。
中国自古便有“药食同源”，本发明采用自然疗法和生物营养疗法，以五脏气血同调方法，解决疾病源头代谢问题为首要的治病原理，调节五脏气血功能，使人体恢复自身吸收代谢排毒功能而达到治疗、预防和/或修复癌症。
发明内容
本发明的目的是提供一种用于治疗、预防和/或修复癌症的复方小球藻组合物，以解决现有技术中的存在的问题。
为实现上述目的，本发明的提供了一种用于治疗、预防和/或修复癌症的复方小球藻组合物。具体的，所述用于治疗、预防和/或修复癌症的复方小球藻组合物按照质量份数包括：蛋白核小球藻粉30～70份、雪莲培养物10～30份和富硒灰树花真菌多糖提取物15～45份。
优选地，所述用于治疗、预防和/或修复癌症的复方小球藻组合物按照质量份数包括：蛋白核小球藻粉40～60份、雪莲培养物15～25份和富硒灰树花真菌多糖提取物20～40份。
优选地，所述用于治疗、预防和/或修复癌症的复方小球藻组合物按照质量份数包括：蛋白核小球藻粉50份、雪莲培养物20份和富硒灰树花真菌多糖提取物30份。
优选地，所述蛋白核小球藻粉的制备方法包括：将蛋白核小球藻藻种接种至养殖池水体中，调节水体pH值至6.5～7.5；加入培养基，植入二氧化碳发生器，20～30℃通入二氧化碳条件下持续光照射5～7天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
优选地，所述水体为自来水或纯净水；所述培养基为葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素。
优选地，所述雪莲培养物的制备方法包括：
将新鲜雪莲培养物置于链条式烘箱70～80℃低温干燥脱水8～10h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；60～80℃低温真空浓缩，喷雾干燥制得雪莲提取物原粉。
优选地，所述粉碎后的雪莲干花与乙醇质量体积比为1：100。
优选地，所述富硒灰树花真菌多糖提取物的制备方法包括：
将富硒灰树花菌丝体发酵原液90～100℃条件下水煮2h，导入碟式离心泵3000r/min，离心10min，保留上清液，去除残渣，40～60℃0.02～0.05Mpa条件下低温真空浓缩2～4h，制得12～18％的多糖浓缩液，转移至浓度为95％的乙醇中放置6～8h，喷雾干燥，制得富硒灰树花真菌多糖提取物。
优选地，所述富硒灰树花菌丝体发酵原液的制备方法包括：
向液体培养基中加入灰树花菌丝体菌种，加入一级种子罐125℃高温灭菌1h，无氧条件下25℃恒温培养5天，导入二级种子罐，无氧条件下25℃恒温培养4天，导入生产性发酵罐，无氧条件下25℃恒温培养4天，制得富硒灰树花菌丝体发酵原液。
优选地，所述液体培养基含有10～200mg/kg硒。
本发明所选用中草药的药性及药理如下：
蛋白核小球藻粉，是一种单细胞微藻植物，含有蛋白质50～67％，含有人体所需的20种氨基酸、多种维生素和微量元素，以及亚麻酸、亚油酸、胡萝卜素等成分。其生物素含量为每100克0.18～0.25毫克，参与碳水化合物，蛋白质和脂肪的代谢；叶绿素每100克含量2.4克，参与排出各种毒素；常量元素镁每100克含量243毫克，参与酶的活化，维持血管的收缩和舒张平衡，避免高血压和动脉粥样硬化。研究证明，小球藻细胞糖蛋白具有显著的抑瘤抗癌、增强免疫和抗病毒感染的活性，小球藻所含未知活性因子具有增强细胞代谢、延缓细胞衰老的活性。
天山雪莲味微苦，性温。归肝、脾、肾三经。有温肾助阳，祛风胜湿，通经活血的作用，主要含有的黄酮及其苷、倍半萜内酯、香豆素、木脂素、有机酸、氨基酸、甾体、多糖等成分。雪莲培养物是从种源—天山雪莲的幼茎切片在培养皿中培养，到细胞组织的形成，细胞组织培养，细胞团的收集，雪莲愈伤组织再分化，形成生芽生根的雪莲苗，使其组织或细胞增殖。2010年国家卫生部批准雪莲培养物为新资源食品，可做为普通食品食用。
灰树花真菌多糖提取物，灰树花含有大量的灰树花多糖、α-D-葡聚糖、β-D-葡聚糖，以β-D-葡聚糖为主，如MT-2，其侧链为β-(1→6)，主链为β-(1→3)葡聚糖，MT-1侧链为β-(1→3)，主链为β-(1→6)葡聚糖等，灰树花子实体中的葡聚糖存在于细胞壁中，在细胞壁骨架外部多为β-(1→6)-葡聚糖，内部为有侧链的β-(1→3)-葡聚糖。灰树花另含有蛋白质、人体必须的氨基酸、维生素、矿物质等，具有调节机体免疫力、抗肿瘤、抗病毒、健胃护肝、降血脂、血糖和胆固醇、抗血栓、抗衰老、抗辐射、祛痰镇咳等多种药理作用。研究发现，灰树花真菌多糖可以通过调节机体免疫功能，如激活自然杀伤细胞、补体及吞噬细胞的作用，达到防癌抗癌的作用。
硒，是动物和人体中一些抗氧化酶和硒-P蛋白的重要组成部分。研究证明，硒能清除体内自由基，排除体内毒素、抗氧化、能有效的抑制过氧化脂质的产生，防止血凝块，清除胆固醇，增强人体免疫功能，由于“硒”的高抗氧化作用，适量补充能起到防止器官老化与病变，延缓衰老，增强免疫，抵御疾病，抵抗有毒害重金属，减轻放化疗副作用，防癌抗癌。同时，血硒水平的高低与癌的发生息息相关，是人体微量元素的“防癌之王”。
本发明方法具有如下优点：
1、本发明的用于治疗、预防和/或修复癌症的复方小球藻组合物，选用排除降解毒素，调节酸碱平衡，均衡营养的蛋白核小球藻粉；软化疏通血管，镇痛消炎，强化造血的雪莲培养物；激活人体免疫系统，诱导肿瘤细胞凋亡的灰树花真菌多糖，三种天然植物提取物进行辩证配伍，以蛋白核小球藻纯粉为主，天山雪莲为辅，配合治疗兼证，灰树花协同真菌多糖活化免疫系统，配合抑制病毒在体内复制，中和或转化自由基的物质的微量元素硒，配伍后可使生物营养有效成分优势互补，起到事半功倍的协调康复效果。
2、本发明选用新资源食品作为配方，活性物质直接到达病变部位，可以快速排除毒素，激活免疫细胞，提升免疫力，且没有任何潜在的健康危害，食用的过程中不会产生任何毒副作用。
3、本发明免于手术和放化疗带来的痛苦，制成产品类型可以为压片糖果，口感好，费用低，易于癌症患者接受，有利于病症从源头上修复癌症对人体造成的损伤。
具体实施方式
以下实施例用于说明本发明，但不用来限制本发明的范围。
实施例1
蛋白核小球藻粉：将40g蛋白核小球藻藻种接种至养殖池自来水中，调节水体pH值至6.8；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，25℃通入二氧化碳条件下持续光照射6天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
雪莲培养物：将500g新鲜雪莲培养物置于链条式烘箱70℃低温干燥脱水9h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；78℃低温真空浓缩，喷雾干燥制得雪莲培养物原粉。
富硒灰树花真菌多糖提取物：向液体培养基(含有120mg/kg硒)中加入15g灰树花菌丝体菌种，加入一级种子罐125℃高温灭菌1h，无氧条件下25℃恒温培养5天，导入二级种子罐，无氧条件下25℃恒温培养4天，导入生产性发酵罐，无氧条件下25℃恒温培养4天，制得富硒灰树花菌丝体发酵原液；
将20mL富硒灰树花菌丝体发酵原液100℃条件下水煮2h，导入碟式离心泵3000r/min，离心10min，保留上清液，去除残渣，50℃0.02Mpa条件下低温真空浓缩2.5h，制得12％的多糖浓缩液，转移至浓度为95％的乙醇中放置6.5h，喷雾干燥，制得富硒灰树花真菌多糖提取物。
然后，将蛋白核小球藻粉50份、雪莲培养物20份和富硒灰树花真菌多糖提取物30份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
实施例2
蛋白核小球藻粉：将30g蛋白核小球藻藻种接种至养殖池自来水中，调节水体pH值至6.5；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，20℃通入二氧化碳条件下持续光照射6.5天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
雪莲培养物：将800g新鲜雪莲培养物置于链条式烘箱76℃低温干燥脱水8h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；60℃低温真空浓缩，喷雾干燥制得雪莲培养物原粉。
富硒灰树花真菌多糖提取物：向液体培养基(含有150mg/kg硒)中加入12g灰树花菌丝体菌种，加入一级种子罐125℃高温灭菌1h，无氧条件下25℃恒温培养5天，导入二级种子罐，无氧条件下25℃恒温培养4天，导入生产性发酵罐，无氧条件下25℃恒温培养4天，制得富硒灰树花菌丝体发酵原液；
将35mL富硒灰树花菌丝体发酵原液98℃条件下水煮2h，导入碟式离心泵3000r/min，离心10min，保留上清液，去除残渣，40℃0.04Mpa条件下低温真空浓缩2h，制得18％的多糖浓缩液，转移至浓度为95％的乙醇中放置6h，喷雾干燥，制得富硒灰树花真菌多糖提取物。
然后，将蛋白核小球藻粉70份、雪莲培养物10份和富硒灰树花真菌多糖提取物20份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
实施例3
蛋白核小球藻粉：将50g蛋白核小球藻藻种接种至养殖池纯净水中，调节水体pH值至7.2；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，30℃通入二氧化碳条件下持续光照射5.5天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
雪莲培养物提取：将1200g新鲜雪莲培养物置于链条式烘箱72℃低温干燥脱水10h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；75℃低温真空浓缩，喷雾干燥制得雪莲培养物原粉。
富硒灰树花真菌多糖提取物：向液体培养基(含有10mg/kg硒)中加入8g灰树花菌丝体菌种，加入一级种子罐125℃高温灭菌1h，无氧条件下25℃恒温培养5天，导入二级种子罐，无氧条件下25℃恒温培养4天，导入生产性发酵罐，无氧条件下25℃恒温培养4天，制得富硒灰树花菌丝体发酵原液；
将50mL富硒灰树花菌丝体发酵原液95℃条件下水煮2h，导入碟式离心泵3000r/min，离心10min，保留上清液，去除残渣，60℃0.02Mpa条件下低温真空浓缩4h，制得15％的多糖浓缩液，转移至浓度为95％的乙醇中放置8h，喷雾干燥，制得富硒灰树花真菌多糖提取物。
然后，将蛋白核小球藻粉40份、雪莲培养物30份和富硒灰树花真菌多糖提取物45份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
实施例4
蛋白核小球藻粉：将60g蛋白核小球藻藻种接种至养殖池纯净水中，调节水体pH值至7.5；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，26℃通入二氧化碳条件下持续光照射7天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
雪莲培养物：将600g新鲜雪莲培养物置于链条式烘箱80℃低温干燥脱水8.5h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；80℃低温真空浓缩，喷雾干燥制得雪莲培养物原粉。
富硒灰树花真菌多糖提取物：向液体培养基(含有200mg/kg硒)中加入29g灰树花菌丝体菌种，加入一级种子罐125℃高温灭菌1h，无氧条件下25℃恒温培养5天，导入二级种子罐，无氧条件下25℃恒温培养4天，导入生产性发酵罐，无氧条件下25℃恒温培养4天，制得富硒灰树花菌丝体发酵原液；
将25mL富硒灰树花菌丝体发酵原液90℃条件下水煮2h，导入碟式离心泵3000r/min，离心10min，保留上清液，去除残渣，55℃0.05Mpa条件下低温真空浓缩3h，制得14％的多糖浓缩液，转移至浓度为95％的乙醇中放置7.5h，喷雾干燥，制得富硒灰树花真菌多糖提取物。
然后，将蛋白核小球藻粉30份、雪莲培养物15份和富硒灰树花真菌多糖提取物40份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
实施例5
蛋白核小球藻粉：将80g蛋白核小球藻藻种接种至养殖池纯净水中，调节水体pH值至7；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，28℃通入二氧化碳条件下持续光照射5天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
雪莲培养物提取：将550g新鲜雪莲培养物置于链条式烘箱78℃低温干燥脱水9h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；65℃低温真空浓缩，喷雾干燥制得雪莲培养物原粉。
富硒灰树花真菌多糖提取物：向液体培养基(含有80mg/kg硒)中加入16g灰树花菌丝体菌种，加入一级种子罐125℃高温灭菌1h，无氧条件下25℃恒温培养5天，导入二级种子罐，无氧条件下25℃恒温培养4天，导入生产性发酵罐，无氧条件下25℃恒温培养4天，制得富硒灰树花菌丝体发酵原液；
将32mL富硒灰树花菌丝体发酵原液99℃条件下水煮2h，导入碟式离心泵3000r/min，离心10min，保留上清液，去除残渣，45℃0.03Mpa条件下低温真空浓缩3.5h，制得16％的多糖浓缩液，转移至浓度为95％的乙醇中放置8h，喷雾干燥，制得富硒灰树花真菌多糖提取物。
然后，将蛋白核小球藻粉60份、雪莲培养物25份和富硒灰树花真菌多糖提取物15份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
典型案例：
河南省南阳市陈女士，现年38岁，三年前检查患有乳腺癌，一直食用各种偏方与中西药，因该说也起到一定治疗缓解作用，但病情未向好转，2016年2月双乳已经发黑，乳头微微腐烂，并流有脓汁，当年三月开始食用高含量天山雪莲培养物、高含量真菌多糖提取物、蛋白核小球藻片。食用一周后，乳头明显减少流脓，现食用一个多月，身体明显感觉好转，乳房颜色得以逐渐恢复。
浙江省杭州市58岁的黄先生，2015年12月14日在浙江省人民医院肺平扫，右肺中叶磨玻璃密度结节，双肺气肿，慢性阻塞性肺病，肺部阴影，在胸外科就诊，拒绝住院。2015年12月22日，黄先生又来医院呼吸内科进行肿瘤标志物糖类抗原72-4检测，结果达53.3uU/ml(正常参考值为0.0-1.9.)。但是他拒绝了放化疗方式治疗，选择非药物营养治疗，食用天山雪莲培养物、液态发酵菌丝体粉和小球藻片新资源配方食品。黄先生食用20天后，于2016年1月13日进行治疗标志物检检查，结果降为45.7/ml，病情明显好转。当年4月22日再次检查，肿瘤标志物糖类抗原72-4达到1.7u/ml,终于回复了正常，经过四个月的生物营养调理，终于重新回到快乐正常的生活。
虽然，上文中已经用一般性说明及具体实施例对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
Claims (10)
1.一种用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述用于治疗、预防和/或修复癌症的复方小球藻组合物按照质量份数包括：蛋白核小球藻粉30～70份、雪莲培养物10～30份和富硒灰树花真菌多糖提取物15～45份。
2.根据权利要求1所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述用于治疗、预防和/或修复癌症的复方小球藻组合物按照质量份数包括：蛋白核小球藻粉40～60份、雪莲培养物15～25份和富硒灰树花真菌多糖提取物20～40份。
3.根据权利要求2所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述用于治疗、预防和/或修复癌症的复方小球藻组合物按照质量份数包括：蛋白核小球藻粉50份、雪莲培养物20份和富硒灰树花真菌多糖提取物30份。
4.根据权利要求1-3任一项所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述蛋白核小球藻粉的制备方法包括：将蛋白核小球藻藻种接种至养殖池水体中，调节水体pH值至6.5～7.5；加入培养基，植入二氧化碳发生器，20～30℃通入二氧化碳条件下持续光照射5～7天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
5.根据权利要求4所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述水体为自来水或纯净水；所述培养基为葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素。
6.根据权利要求1-3任一项所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述雪莲培养物的制备方法包括：
将新鲜雪莲培养物置于链条式烘箱70～80℃低温干燥脱水8～10h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；60～80℃低温真空浓缩，喷雾干燥制得雪莲培养物原粉。
7.根据权利要求6所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述粉碎后的雪莲干花与乙醇质量体积比为1：100。
8.根据权利要求1-3任一项所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述富硒灰树花真菌多糖提取物的制备方法包括：
将富硒灰树花菌丝体发酵原液90～100℃条件下水煮2h，导入碟式离心泵3000r/min，离心10min，保留上清液，去除残渣，40～60℃0.02～0.05Mpa条件下低温真空浓缩2～4h，制得12～18％的多糖浓缩液，转移至浓度为95％的乙醇中放置6～8h，喷雾干燥，制得富硒灰树花真菌多糖提取物。
9.根据权利要求8所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述富硒灰树花菌丝体发酵原液的制备方法包括：
向液体培养基中加入灰树花菌丝体菌种，加入一级种子罐125℃高温灭菌1h，无氧条件下25℃恒温培养5天，导入二级种子罐，无氧条件下25℃恒温培养4天，导入生产性发酵罐，无氧条件下25℃恒温培养4天，制得富硒灰树花菌丝体发酵原液。
10.根据权利要求8所述的用于治疗、预防和/或修复癌症的复方小球藻组合物，其特征在于：所述液体培养基含有10～200mg/kg硒。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810205334.0A CN108477611A (zh) | 2018-03-13 | 2018-03-13 | 一种用于治疗、预防和/或修复癌症的复方小球藻组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810205334.0A CN108477611A (zh) | 2018-03-13 | 2018-03-13 | 一种用于治疗、预防和/或修复癌症的复方小球藻组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108477611A true CN108477611A (zh) | 2018-09-04 |
Family
ID=63339036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810205334.0A Pending CN108477611A (zh) | 2018-03-13 | 2018-03-13 | 一种用于治疗、预防和/或修复癌症的复方小球藻组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108477611A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110973632A (zh) * | 2019-12-25 | 2020-04-10 | 康波 | 一种进行癌症膳食干预的膳食组合物及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62123128A (ja) * | 1986-07-11 | 1987-06-04 | Asahi Glass Co Ltd | ヨウ素含有淡水クロレラおよびそれを主成分とする抗癌剤 |
| JP2005089321A (ja) * | 2003-09-12 | 2005-04-07 | Sun Chlorella Corp | ホルボールエステル受容体結合阻害剤 |
| CN106749719A (zh) * | 2016-12-05 | 2017-05-31 | 江苏大学 | 一种富硒灰树花硒多糖及其制备方法和应用 |
| CN107007646A (zh) * | 2017-03-14 | 2017-08-04 | 郑笃达 | 一种辅助防治癌症的营养复合物 |
-
2018
- 2018-03-13 CN CN201810205334.0A patent/CN108477611A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62123128A (ja) * | 1986-07-11 | 1987-06-04 | Asahi Glass Co Ltd | ヨウ素含有淡水クロレラおよびそれを主成分とする抗癌剤 |
| JP2005089321A (ja) * | 2003-09-12 | 2005-04-07 | Sun Chlorella Corp | ホルボールエステル受容体結合阻害剤 |
| CN106749719A (zh) * | 2016-12-05 | 2017-05-31 | 江苏大学 | 一种富硒灰树花硒多糖及其制备方法和应用 |
| CN107007646A (zh) * | 2017-03-14 | 2017-08-04 | 郑笃达 | 一种辅助防治癌症的营养复合物 |
Non-Patent Citations (2)
| Title |
|---|
| 侯团章: "《中草药提取物 第1卷》", 31 July 2004, 中国医药科技出版社 * |
| 茆广华: ""灰树花子实体富硒及其硒多糖的研究"", 《中国博士学位论文全文数据库 工程科技Ⅰ辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110973632A (zh) * | 2019-12-25 | 2020-04-10 | 康波 | 一种进行癌症膳食干预的膳食组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101624570B (zh) | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 | |
| CN106473107A (zh) | 一种即食型复合食用菌粉营养素及其制备方法 | |
| CN105639525A (zh) | 护肝排毒果蔬酵素及其制备方法 | |
| CN107155639A (zh) | 一种富含1‑脱氧野尻霉素的北虫草的培养方法 | |
| CN102488278A (zh) | 一种具有双功能保健作用的复合真菌营养液 | |
| CN1676036B (zh) | 灵芝金刚根保健食品及其制备方法 | |
| CN104479946A (zh) | 黄秋葵、菌、藻植物组合物制作营养露酒的方法 | |
| CN107652048A (zh) | 一种香菇增强免疫作用的栽培基质及其制备方法 | |
| CN106148200A (zh) | 一种富硒低铅、砷的冬虫夏草菌丝体的培养基及其培植方法 | |
| CN103829249A (zh) | 一种调理脾胃湿热体质酵素及其制备方法 | |
| CN101104006B (zh) | 一种冬虫夏草菌提取浓缩液的制备方法及其应用 | |
| CN104479964A (zh) | 一种黄秋葵、菌、藻保健酒及其制备方法 | |
| CN106588300A (zh) | 一种富硒梨的种植方法 | |
| CN104892284A (zh) | 一种栽培云耳的培养基 | |
| CN105198638A (zh) | 一种富硒高钙食用菌菇的栽培方法 | |
| CN108477611A (zh) | 一种用于治疗、预防和/或修复癌症的复方小球藻组合物 | |
| CN104940241B (zh) | 一种防治妇女更年期综合征的硒虫草复方制剂 | |
| CN103829248A (zh) | 一种调理肝胆湿热体质酵素及其制备方法 | |
| CN106085878A (zh) | 一种辣木香菇菌丝体的培育方法 | |
| CN109198123A (zh) | 一种桑黄保健茶及其制备方法 | |
| CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
| KR101220131B1 (ko) | 효소 현미 및 효소 현미의 제조 방법 | |
| CN104906140A (zh) | 一种阿胶及其制备方法与相关设备 | |
| CN104430720A (zh) | 黄秋葵、菌、藻植物组合物制作功能性饼干的方法 | |
| CN107898920A (zh) | 一种用于糖尿病的口含制品与制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180904 |